92 results about "Corneal ulcer" patented technology

The invention provides an ophthalmic, otic or nasal pharmaceutical composition, comprising levofloxacin or the pharmaceutical acceptable salts thereof and loteprednol etabonate, wherein the weight ratio of loteprednol etabonate to levofloxacin is 1:0.2-5. The use of ophthalmic, otic or nasal pharmaceutical composition of the invention in preparation of the medication for treatment of conjunctivitis, keratitis, blepharitis, dacrycystitis, hordeolum, corneal ulcer and ocular infection accompanied with ophthalmitis and even inflammation of the surrounding tissues, to prevent increase of bacterial infection risks and the tissue inflammation of the infected area after the ophthalmic surgeries or ocular injuries, to treat or alleviate the bacterial infection in combination with the tissue inflammation of the infected area, or to treat tympanitis, otitis externa and infective rhinitis.

The invention discloses a method and application for preparing a tissue engineering corneal carrier stent by utilizing fresh porcine cornea. The method comprises the following steps: cutting a fresh porcine cornea for swelling, repeatedly freeze thawing and breaking cells, removing residual nucleic acid substances through DNA-RNA enzyme treatment, cross-linking, airing, and finally performing irradiation sterilization through ionization rays, thereby obtaining the product. The method is applied to carrier stents of tissue engineering corneal epithelium, stroma, endothelium, front board layer half cornea, rear board layer half cornea and full-layer board layer half cornea, so that the requirement on batch production of tissue engineering corneas is met. The carrier stent serves as a substitute of human corneal stroma to be used for clinical transplant and treatment of un-accumulated whole layer keratohelcosis. The method is applied to large-scale production and clinical popularization and application. The prepared carrier stent has the characteristics of high transparency, dense structure, high mechanical property, high biocompatibility with human corneal seed cells and the like. Therefore, the method is suitable for batch production, so that the requirements on lots of carrier stents for tissue engineering corneas are met.

The present invention relates to medicine technology, and is one kind of eye drops for treating conjunctivitis, keraritis, corneal ulcer, xerophthalma and other eye diseases. The eye drops contains water soluble chitosan derivative and medicinal active component, proper amount of pH controlling agent and osmotic pressure regulator. It has delayed releasing and long acting function and thus high biological medicine utilization and clinical curative effect.

An ocular Jiatishaxing gel for treating eyelid inflammation, stye, conjunctivitis, dacryocystitis, keratitis, corneal ulcer and trachoma is prepared from Jiatishaxing, HPMC as matrix, antiseptic, isotonic regulator, osmotic promoter, pH regulator and water through dissolving Jiatishaxing in water, adding others, stirring, regulating pH=5-9, filter and adding water.

An eyedrops able to become gel after it is dropped in eye for treating bacterial conjuctivities, keratitis, keratohelcosis, dacryocystitis, etc is prepared from antibacterial infilammatino-relieving medicine, thickening agent, antiseptic, isotonic regulator, pH regulator and water. Its advantages are long stay time in eye, high curative effect, and low poison and irritation.

The invention concerns the use of inhibitors of the urokinase type of plasminogen activator (uPA) appearing in the anterior segment of the eye, for the treatment and prevention of corneal ulcers and other disorders. The invention further concerns pharmaceutical compositions, comprising inhibitors of uPA, preferably eye drops and eye ointments. The pharmaceutical compositions according to the invention preferably comprise PAI-2 protein or a derivative thereof retaining uPA-inhibiting capacity, or a tripeptide aldehyde inhibitor, preferably the D-Phe-Pro-Arg-aldehyde (Ald-1). The PAI-2 protein, used according to the invention, is preferably produced through bacterial expression, as a fusion protein.

The invention relates to the technical field of eye dressings and in particular relates to a medical biological eye cold therapy dressing and a preparation method thereof. The medical biological eye cold therapy functional dressing is prepared from the following components: sorbitol, hyaluronic acid, pearl powder, peppermint oil, borneol, a mother chrysanthemum extracting solution, cassia seed extractive and a balsam pear extracting solution. The medical biological eye cold therapy dressing has functions of diminishing inflammation and swelling, easing pain and keeping moist of eyes for a long time, is used for improving and auxiliary treating of symptoms of dry eyes, eyestrain, eye itching, eye swelling, black eyes, lacrimation, secretion increase, asthenopia, corneal ulcer and the like caused by reasons of myopia, cataract, presbyopia, glaucoma, excessive eye and the like and has function of improving amblyopia.

The invention relates to a kind of compound collagen protein gutta, which is the mixture of collagen protein and antibiotics. For every 100ml compound collagen gutta, there is 10-500mg collagen protein which is extracted from the tendon, 100-600mg antibiotics which include one or two kinds of the following antibiotics: ofloxacin, alficetin, tenebrimycin, while the rest is the iso-osmia, which is 5% amylaceum solution. The product has three main functions: resist bacteria and inflammation; help to keep the eyeball moist, promote the agglutination and relieve the asthenopia; be used in the treatment of the damage to the cornea, keratohelcosis, keratitis punctata, slight chemical injury to cornea as well as the thermal damage to the cornea; prevent the ophthalmia and relieve the asthenopia; prevent the cohesive property of the collagen from being diluted so as to extend the effective time of the gutta; resist the bacteria as well as promote the agglutination.

The invention provides ophthalmic bacterial-infection resisting medicine for external use. Linezolid is adopted as medicative raw materials to prepare eye drops, ophthalmic gel and eye ointments. The content of the linezolid in every 100 parts by weight of a medicament is within 0.1 to 1.0 parts by weight. The medicine is for external use at partial positions of eyes, and has good intraocular penetrability and mild toxic as well as side effects; moreover, the medicine is suitable for treating as well as preventing bacterial infection at partial positions of the eyes, including diseases of conjunctivitis, keratitis, keratohelcosis, iritis, ocular traumas, chemical injuries, ophthalmic postoperative infections and the like.

The Gatifloxacin gel preparation for external use and eye use has Gatifloxacin as main component and its supplementary material includes chitosan as gel substrate, iso-osmotic regulator, pH regulator, preservative, injection water, etc. The preparation has Gatifloxacin content of 0.1-3 wt% and chitosan content of 0.3-3 wt%. It has obvious anti-infection function and functions of speeding heal of wound, promoting epidermal growth, inhibiting formation of scar tissue, maintaining local medicine density for long term, etc. It is used in treating burns, scalds, skin infection, folliculitis, bacterial conjunctivitis, keratitis, etc.

The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RARγ agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis. The therapeutic agent is also useful as a therapeutic agent for corneal scarring and conjunctival scarring both associated with keratoconjunctive disorders.

The invention discloses a 1,2,3-trihydroxy benzene and derivant or pharmacy acceptable salt for zinc ion metal-prolease inhibition, which is characterized by the following: theses compounds is used for selective depressant of zinc ion metal-prolease (such as MT1-MMP, gelatinase A, B and collagenase, matrilysins, metal-elastase and stromelysin-1); these depressants can adjust physiological and pathology course with MMPs, ADAMs, ADAM-TS such as vessel rebirth, wound healing, organ transplantation, fecundation course and reactivation capability, rebuilding bone and ache, which is used for treating cancer, cardiovascular disease, arthritis, periodontal disease, multiple sclerosis, inflammation, adenomyosis, cornea ulcer, bacterial meningitis, diabetic syndrome, kidney disease, nerve retrogression disease, AIDS, bleb, anaphylaxis, adenomyosis, osteoporosis, asthma and so on; theses blocking agents can be used for antisenescence, antibiosis, commercial manufacture addition agent of cell epimatrix, collagen product, cosmetics and make-up preparation, which can used for animals and other living bodies.

The present invention provides an external preparation and the method for produce the same, in which said external preparation comprises recombinant human growth hormone or recombinant human granulocyte macrophage-stimulating factor and pharmaceutical acceptable carriers. The present invention also relates to application and usage method in preparing medicaments for treatment of various lesions and ulcer, especially corneal lesion and corneal ulcer.

The invention discloses a method for preparing a cornea lamina material. The method comprises the following steps of: carrying out accellular processing on a cornea-sclera complex of a mammal eyeball, culturing an amnion epithelial stem cell, inducing and secreting TSP (Thrombospondin)-1 and co-culturing accellular cornea stroma and the amnion epithelial stem cell, sizing, packaging and sterilizing, and the like. According to an obtained cornea lamina transplanting material, the promotion and the balance among the biocompatibility, the stability, the transparency, the mechanical strength and the bioactivity are realized; the integrity of cornea collagen molecules and a lamina structure can be kept to the largest extent, and compared with that prepared with the traditional method, the accellular cornea stroma prepared according to the method disclosed by the invention is larger in tensile strength and has the moisture content and the transparency close to those of normal cornea; and various cell growth factors and the TSP-1 are gathered, and the cornea lamina material has special effects of inflammatory resistance and vascularization resistance, has the capability of greatly enhancing the bioactivity of the cornea lamina material and can be widely used for repairing complicated ocular surface coloboma such as inflammation and corneal ulcer grown in a vascularization way.

An object of the present invention is to provide a new medicinal use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent prevention and improvement effect in corneal disorder models, and is therefore useful as a preventive or therapeutic agent for a keratoconjunctival disorder such as dry eye, superficial punctate keratopathy, corneal epithelial defects, corneal erosion, corneal ulcer, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, keratitis or conjunctivitis.

Object of the present invention is to search a novel pharmaceutical use of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl] thiazolidine-2, 4-dione being a condensed heterocyclic compound, or a salt thereof. 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl] thiazolidine-2, 4-dione or a salt thereof can exert an excellent effect to promote healing in a dry eye model, and is useful as a therapeutic agent for keratoconjunctival disorders such as dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis and filamentary keratitis.